|
C20ORF94 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 3.48769999991561E-07 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.71030000162276E-08 |
| Normal-vs-Stage2 |
1.722550E-03 |
| Normal-vs-Stage3 |
1.93160000216963E-08 |
| Normal-vs-Stage4 |
2.44740000043819E-07 |
| Stage1-vs-Stage2 |
3.847600E-01 |
| Stage1-vs-Stage3 |
2.922000E-02 |
| Stage1-vs-Stage4 |
1.909200E-01 |
| Stage2-vs-Stage3 |
4.886500E-02 |
| Stage2-vs-Stage4 |
9.281900E-02 |
| Stage3-vs-Stage4 |
8.742200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
2.72790000033218E-07 |
| Normal-vs-AfricanAmerican |
8.864600E-03 |
| Normal-vs-Asian |
8.05740000053845E-07 |
| Caucasian-vs-AfricanAmerican |
2.437600E-01 |
| Caucasian-vs-Asian |
4.119200E-01 |
| AfricanAmerican-vs-Asian |
1.289570E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
6.38570000210947E-08 |
| Normal-vs-Female |
4.61750000013694E-07 |
| Male-vs-Female |
8.176400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.41570000003577E-06 |
| Normal-vs-Age(41-60Yrs) |
1.46519996135908E-09 |
| Normal-vs-Age(61-80Yrs) |
1.79519999998767E-06 |
| Normal-vs-Age(81-100Yrs) |
1.721660E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.078400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
7.050800E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
7.024200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
6.159000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.602400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.048600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.756300E-04 |
| Classical-VS-Follicular |
5.483800E-01 |
| Classical-VS-Other |
1.543780E-01 |
| Classical-VS-Normal |
3.80929999999058E-06 |
| Tall-VS-Follicular |
1.834210E-02 |
| Tall-VS-Other |
9.205800E-01 |
| Tall-VS-Normal |
1.77339998241877E-09 |
| Follicular-VS-Other |
3.138000E-01 |
| Follicular-VS-Normal |
2.97620000000443E-06 |
| Other-VS-Normal |
3.781700E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
5.33049999695834E-08 |
| Normal-vs-N1 |
1.94690000010489E-07 |
| N0-vs-N1 |
2.195200E-01 |
|
|
